Treatment of sarcoidosis-associated pulmonary hypertension: A single centre retrospective experience using targeted therapies.

BACKGROUND Pulmonary hypertension (PH), an increasingly recognised complication of pulmonary sarcoidosis, is associated with increased morbidity and mortality Evidence of benefit with targeted therapies in sarcoidosis associated pulmonary hypertension (SAPH) is limited. METHODS We conducted a retrospective review of patients with sarcoidosis and right heart catheter proven PH who received treatment with targeted therapies (phosphodiesterase-5 inhibitors, endothelin receptor antagonists, or combination) at our hospital. Six minute walk test (6MWT), World Health Organisation (WHO) functional class, echocardiography, pulmonary function test (PFT) and serum brain natriuretic peptide (BNP) data were collected at baseline and during follow-up. RESULTS Thirty-three patients (16 men) with a mean age of 55.5 ± 10.7 years and mean pulmonary artery pressure of 44.0 ± 8.6 mm Hg received treatment with targeted PH therapies (sildenafil=29, bosentan=4). At six months, median six minute walk distance improved from 227 (88-526) meters to 240 (140-380) metres (p=0.04), median serum BNP levels improved from 35 (2-424) pmol/L to 26 (4-255) pmol/L (p<0.01), and at echocardiography, median tricuspid annular plane systolic excursion (TAPSE) improved from 17.5 (8.0-27.0) mm to 20.0 (15.0-27.0) mm (p=0.03). WHO functional class improved in 14 patients. Two patients developed side-effects attributed to sildenafil (n=1) or bosentan (n=1), requiring conversion to alternative PH therapies. Ten patients died, and one patient underwent lung transplantation, a median of 13.5 (3-37) months after commencing targeted therapies. CONCLUSIONS Our results suggest that targeted therapies are safe in patients with SAPH. Controlled trials are warranted before therapeutic recommendations can be made.

[1]  S. Nathan,et al.  Pulmonary Hypertension in Sarcoidosis. , 2015, Clinics in chest medicine.

[2]  M. Puhan,et al.  The minimal important difference in the 6-minute walk test for patients with pulmonary arterial hypertension. , 2012, American journal of respiratory and critical care medicine.

[3]  K. Dimopoulos,et al.  Echocardiographic Predictors of Outcome in Eisenmenger Syndrome , 2012, Circulation.

[4]  D. Hansell,et al.  Pulmonary Sarcoidosis: Integration Of The Composite Physiologocal Index And HRCT Patterns For Clinical Staging , 2012, ATS 2012.

[5]  James O. Mudd,et al.  Tricuspid Annular Plane Systolic Excursion Is a Robust Outcome Measure in Systemic Sclerosis-associated Pulmonary Arterial Hypertension , 2011, The Journal of Rheumatology.

[6]  Justin D. Roberts,et al.  Serial TAPSE at 1 Year, Not Baseline TAPSE, Predicts Survival Differences in Patients With an Incident Diagnosis of Pulmonary Arterial Hypertension , 2011 .

[7]  S. Sahn,et al.  Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference. , 2011, American journal of respiratory and critical care medicine.

[8]  R. Baughman,et al.  Survival in sarcoidosis-associated pulmonary hypertension: the importance of hemodynamic evaluation. , 2010, Chest.

[9]  K. Chin,et al.  Significance of plasma NT-proBNP levels as a biomarker in the assessment of cardiac involvement and pulmonary hypertension in patients with sarcoidosis. , 2010, Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG.

[10]  G. Giannakoulas,et al.  Elevated brain natriuretic peptide predicts mortality in interstitial lung disease , 2010, European Respiratory Journal.

[11]  R. Baughman,et al.  Inhaled iloprost for sarcoidosis associated pulmonary hypertension. , 2009, Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG.

[12]  D. Hansell,et al.  Computed tomography signs of pulmonary hypertension: old and new observations. , 2009, Clinical radiology.

[13]  Horst Olschewski,et al.  Updated clinical classification of pulmonary hypertension. , 2009, Journal of the American College of Cardiology.

[14]  D. Hansell,et al.  Pulmonary vascular resistance predicts early mortality in patients with diffuse fibrotic lung disease and suspected pulmonary hypertension , 2009, Thorax.

[15]  S. Nathan,et al.  Treatment of sarcoidosis-associated pulmonary hypertension. A two-center experience. , 2009, Chest.

[16]  H. Palevsky,et al.  Serial Changes in TAPSE Correlate with Functional Assessment and Clinical Events in Patients with PAH. , 2009, ATS 2009.

[17]  C. Strange,et al.  Limitations to the 6-Minute Walk Test in Interstitial Lung Disease and Pulmonary Hypertension in Scleroderma , 2009, The Journal of Rheumatology.

[18]  G. Raghu,et al.  Treatment of idiopathic pulmonary fibrosis with etanercept: an exploratory, placebo-controlled trial. , 2008, American journal of respiratory and critical care medicine.

[19]  L. Samavati,et al.  Clinical predictors of pulmonary hypertension in sarcoidosis , 2008, European Respiratory Journal.

[20]  G. Simonneau,et al.  Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial , 2008, The Lancet.

[21]  E. Hachulla.  Effects of Beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension : a randomized, double-blind, placebo-controlled trial. , 2008 .

[22]  N. Milman,et al.  Pulmonary hypertension in end-stage pulmonary sarcoidosis: therapeutic effect of sildenafil? , 2008, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[23]  M. Humbert,et al.  Immunosuppressive therapy in lupus- and mixed connective tissue disease-associated pulmonary arterial hypertension: a retrospective analysis of twenty-three cases. , 2008, Arthritis and rheumatism.

[24]  R. Baughman,et al.  Six-minute walk test in managing and monitoring sarcoidosis patients , 2007, Current opinion in pulmonary medicine.

[25]  T. Abraham,et al.  Tricuspid annular displacement predicts survival in pulmonary hypertension. , 2006, American journal of respiratory and critical care medicine.

[26]  K. Wilson,et al.  Sarcoidosis-associated pulmonary hypertension: outcome with long-term epoprostenol treatment. , 2006, Chest.

[27]  M. Humbert,et al.  Immunosuppressive therapy in connective tissue diseases-associated pulmonary arterial hypertension. , 2006, Chest.

[28]  R. Barst,et al.  Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan. , 2006, Journal of the American College of Cardiology.

[29]  M. Mishima,et al.  Incidence of pulmonary hypertension and its clinical relevance in patients with sarcoidosis. , 2006, Chest.

[30]  J. Behr,et al.  Brain natriuretic peptide is a prognostic parameter in chronic lung disease. , 2006, American journal of respiratory and critical care medicine.

[31]  M. Humbert,et al.  Pulmonary hypertension associated with sarcoidosis: mechanisms, haemodynamics and prognosis , 2005, Thorax.

[32]  M. Vogeser,et al.  Characterization of brain natriuretic peptide in long-term follow-up of pulmonary arterial hypertension. , 2005, Chest.

[33]  A. Teirstein,et al.  Distinctive clinical, radiographic, and functional characteristics of patients with sarcoidosis-related pulmonary hypertension. , 2005, Chest.

[34]  A. Wells,et al.  Six-minute walk, maximal exercise tests: reproducibility in fibrotic interstitial pneumonia. , 2005, American journal of respiratory and critical care medicine.

[35]  S. Nathan,et al.  Pulmonary hypertension in advanced sarcoidosis: epidemiology and clinical characteristics , 2005, European Respiratory Journal.

[36]  S. Nathan,et al.  Predicting mortality in patients with sarcoidosis awaiting lung transplantation. , 2003, Chest.

[37]  M. Sutton,et al.  Echocardiographic assessment of pulmonary hypertension in patients with advanced lung disease. , 2003, American journal of respiratory and critical care medicine.

[38]  D. Chemla,et al.  Haemodynamic evaluation of pulmonary hypertension , 2002, European Respiratory Journal.

[39]  N. Hill,et al.  Vasoresponsiveness of sarcoidosis-associated pulmonary hypertension. , 2001, Chest.

[40]  J. Bavaria,et al.  Characteristics and outcomes of patients with sarcoidosis listed for lung transplantation. , 2001, Chest.

[41]  C. Ng,et al.  A CT sign of chronic pulmonary arterial hypertension: the ratio of main pulmonary artery to aortic diameter. , 1999, Journal of thoracic imaging.

[42]  G. Hunninghake,et al.  ATS/ERS/WASOG statement on sarcoidosis. American Thoracic Society/European Respiratory Society/World Association of Sarcoidosis and other Granulomatous Disorders. , 1999, Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG.

[43]  E H Bergofsky,et al.  Survival in Patients with Primary Pulmonary Hypertension: Results from a National Prospective Registry , 1991 .

[44]  F. Basset,et al.  Chronic cor pulmonale in pulmonary sarcoidosis. , 1978, Thorax.

[45]  G. Raghu,et al.  BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. , 2008, American journal of respiratory and critical care medicine.

[46]  S. Kuribayashi,et al.  Plasma brain natriuretic peptide levels increase in proportion to the extent of right ventricular dysfunction in pulmonary hypertension. , 1998, Journal of the American College of Cardiology.

[47]  F. Portier,et al.  [Sarcoidosis simulating a pulmonary veno-occlusive disease]. , 1991, Revue des maladies respiratoires.